Medtronic is recalling certain esophageal pH monitoring capsule delivery devices amid the risk of them failing whilst ...

Novocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that ...

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...

Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small ...

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused ...

About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot, laying off most of its employees and seeking new homes for its assets. ArsenalBio is turning to ...

Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned. | Novartis and Bristol Myers Squibb have halted ...

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...

The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. | ...

As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own ...

AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups. | AstraZeneca’s oral relaxin ...

A new report on the health of the Massachusetts biotech scene has painted a mixed picture of how drug developers are faring ...